Enhancing anticancer effects, decreasing risks and solving practical problems facing 3-bromopyruvate in clinical oncology: 10 years of research experience

References

• El SayedSMBaghdadiHZolalyMAlmaramhyHHAyatMDonkiJGThe promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based viewMed Hypotheses2017100677728236852
   PubMed Web of Science ®Google Scholar
• El SayedSMMohamedWGSeddikMASafety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case studyChin J Cancer201433735636424636230
   PubMedGoogle Scholar
• LisPDylągMNiedźwieckaKThe HK2 dependent “War-burg effect” and mitochondrial oxidative phosphorylation in cancer: targets for effective therapy with 3-bromopyruvateMolecules20162112E173027983708
   PubMed Web of Science ®Google Scholar
• El SayedSMEl-MagdRMShishidoY3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effectsJ Bioenerg Biomembr2012441617922318356
   PubMed Web of Science ®Google Scholar
• El SayedSMEl-MagdRMShishidoYD-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effectsJ Bioenerg Biomembr201244551352322802136
   PubMed Web of Science ®Google Scholar
• WuLXuJYuanWThe reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cellsPLoS One2014911e11213225372840
   PubMed Web of Science ®Google Scholar
• KoYHSmithBLWangYAdvanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATPBiochem Biophys Res Commun2004324126927515465013
   PubMed Web of Science ®Google Scholar
• QinJZXinHNickoloffBJ3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell linesBiochem Biophys Res Commun2010396249550020430010
   PubMed Web of Science ®Google Scholar
• MaedaHWuJSawaTMatsumuraYHoriKTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ Control Release2000651–227128410699287
   PubMed Web of Science ®Google Scholar
• WicksRTAzadiJMangravitiALocal delivery of cancer-cell glycolytic inhibitors in high-grade gliomaNeuro Oncol2015171708025053853
   PubMed Web of Science ®Google Scholar
• El SayedSMMahmoudAAEl SawySAWarburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect)Med Hypotheses201381586687024071366
   PubMed Web of Science ®Google Scholar
• GhannamMMEl GebalyRFadelMTargeting doxorubicin encapsulated in stealth liposomes to solid tumors by non thermal diode laserLipids Health Dis2016156827044538
   PubMed Web of Science ®Google Scholar
• VoineaMSimionescuMDesigning of ‘intelligent’ liposomes for efficient delivery of drugsJ Cell Mol Med20026446547412611636
   PubMed Web of Science ®Google Scholar
• GandhamSKTalekarMSinghAAmijiMMInhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysisInt J Nanomedicine2015104405442326185443
   PubMed Web of Science ®Google Scholar
• ZhaoWZhuangSQiXRXrQComparative study of the in vitro and in vivo characteristics of cationic and neutral liposomesInt J Nanomedicine201163087309822163162
   PubMed Web of Science ®Google Scholar
• GuoXSzokaFCSteric stabilization of fusogenic liposomes by a low-pH sensitive PEG – diortho ester – lipid conjugateBioconjug Chem200112229130011312691
   PubMed Web of Science ®Google Scholar
• GlickMBiddlePJantziJWeaverSSchirchDThe antitumor agent 3-bromopyruvate has a short half-life at physiological conditionsBiochem Biophys Res Commun2014452117017325152397
   PubMed Web of Science ®Google Scholar
• FülöpASammourDAErichKMolecular imaging of brain localization of liposomes in mice using MALDI mass spectrometrySci Rep201663379127650487
   PubMed Web of Science ®Google Scholar
• TorchilinVPPassive and active drug targeting: drug delivery to tumors as an exampleHandb Exp Pharmacol2010197197353
   Google Scholar
• WangMThanouMTargeting nanoparticles to cancerPharmacol Res2010622909920380880
   PubMed Web of Science ®Google Scholar
• TorchilinVPTargeted pharmaceutical nanocarriers for cancer therapy and imagingAAPPS J200792E128E147
   PubMed Web of Science ®Google Scholar
• ByrneJDBetancourtTBrannon-PeppasLActive targeting schemes for nanoparticle systems in cancer therapeuticsAdv Drug Deliv Rev200860151615162618840489
   PubMed Web of Science ®Google Scholar
• NagobaBSPunpaleAPoddarASuryawanshiNMSwamiGASelkarSPCitric acid treatment of chronic nonhealing ulcerated tophaceous gout with bursitisInt J Low Extrem Wounds201312427627824275755
   PubMed Web of Science ®Google Scholar
• HaleyBFrenkelENanoparticles for drug delivery in cancer treatmentUrol Oncol2008261576418190833
   PubMed Web of Science ®Google Scholar
• TorchilinVTumor delivery of macromolecular drugs based on the EPR effectAdv Drug Deliv Rev201163313113520304019
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFHenninkWEStormGDrug targeting to tumors: principles, pitfalls and (pre-) clinical progressJ Control Release2012161217518721945285
   PubMed Web of Science ®Google Scholar
• SawantRRTorchilinVPChallenges in development of targeted liposomal therapeuticsAAPS J201214230331522415612
   PubMed Web of Science ®Google Scholar
• LiechtyWBPeppasNAExpert opinion: Responsive polymer nanoparticles in cancer therapyEur J Pharm Biopharm201280224124621888972
   PubMed Web of Science ®Google Scholar
• KularatneSALowPSTargeting of nanoparticles: folate receptorMethods Mol Biol201062424926520217601
   PubMedGoogle Scholar
• LiXDingLXuYWangYPingQTargeted delivery of doxorubicin using stealth liposomes modified with transferrinInt J Pharm20093731–211612319429296
   PubMed Web of Science ®Google Scholar
• ZhaiGWuJYuBGuoCYangXLeeRJA transferrin receptor-targeted liposomal formulation for docetaxelJ Nanosci Nanotechnol20101085129513621125861
   PubMed Web of Science ®Google Scholar
• DanhierFFeronOPréatVTo exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug deliveryJ Control Release2010148213514620797419
   PubMed Web of Science ®Google Scholar
• KorenEApteAJaniATorchilinVPMultifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicityJ Control Release2012160226427322182771
   PubMed Web of Science ®Google Scholar
• GindyMEPrud’hommeRKMultifunctional nanoparticles for imaging, delivery and targeting in cancer therapyExpert Opin Drug Deliv20096886587819637974
   PubMed Web of Science ®Google Scholar
• PaszkoESengeMOImmunoliposomesCurr Med Chem201219315239527722934774
   PubMed Web of Science ®Google Scholar
• van WoenselMWauthozNRosièreRFormulations for intra-nasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM?Cancers2013531020104824202332
   PubMedGoogle Scholar
• ChenTCda FonsecaCOSchönthalAHPerillyl alcohol and its drug-conjugated derivatives as potential novel methods of treating brain metastasesInt J Mol Sci20161791463
   PubMed Web of Science ®Google Scholar
• ZhangQPanJNorthPEAerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicityCancer Prev Res201255717725
   PubMed Web of Science ®Google Scholar
• ChenTCYuJNouri NigjehEA perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cellsCancer Lett201740017161174 S0304-383528450161
   PubMedGoogle Scholar
• MeureLAKnottRFosterNRDehghaniFThe depressurization of an expanded solution into aqueous media for the bulk production of liposomesLangmuir200925132633719072018
   PubMed Web of Science ®Google Scholar